Continue using paclitaxel-eluting PAD devices

Thursday, June 27, 2019

This week's top stories in cardiology:

FDA Panel: Continue using paclitaxel-eluting PAD Devices, with caveats.
Although the benefits of the devices were clear, the panel felt there should be a label change to warn of the late mortality signal seen in a key meta-analysis.
Many cardiac cath, electrophysiology lab directors receive big industry payments
These payments were substantially higher than those made to local interventional cardiologists and electrophysiologist.
Two trials support shorter DAPT
DAPT with a twist: Continuing the P2Y12 inhibitor instead of aspirin.
Do black patients with type 2 diabetes gain cardiac benefit from the SGLT2 and GLP-1 drugs?
New findings suggest there is no effect on cardiovascular outcomes, although the analysis has limitations

How to Listen

Podcast Participants

^{Jim Dwyer, MD}

Jim Dwyer MD, FACC, FSCAI, is a cardiologist and avid horseman in Prescott, Ariz. Trained at Saint Louis University, he spent more than 30 years in interventional cardiology. He recently hung up his lead apron and has joined a private cardiology practice. Dr. Dwyer has been producing health segments for radio broadcast for 20 years. He has no disclosures.